Baird lowered the firm’s price target on Crispr Therapeutics (CRSP) to $44 from $52 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results which met expectations but where Casgevy represents a potential headwind.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics price target lowered to $69 from $70 at JPMorgan
- Crispr Therapeutics AG: Hold Rating Amid Financial Challenges and Mixed Pipeline Progress
- Crispr Therapeutics price target lowered to $50 from $52 at Clear Street
- Crispr Therapeutics reports Q3 EPS ($1.17), consensus ($1.29)
- Promising Prospects for Crispr Therapeutics AG: CTX310’s Breakthrough in Cardiovascular Care